mik665
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 26, 2017 (NCT02992483)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mik665
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04702425 | Phase 1 | Jun 23, 2021 | Novartis |
| NCT04629443 | Phase 1/Phase 2 (Phase 2) | Nov 16, 2020 | Servier |
| NCT03672695 | Phase 1 | Dec 3, 2018 | Monash University, Servier |
| NCT02992483 | Phase 1 | May 26, 2017 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 1 | 2017 |
| Servier | For profit | 2 | 2 | 2 | 2018 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1